COVID-19 in Colombia endpoints. Are we different, like Europe?

被引:27
作者
Amariles, Pedro [1 ,2 ]
Granados, Johan [1 ,2 ]
Ceballos, Mauricio [1 ,2 ]
Montoya, Carlos Julio [1 ]
机构
[1] Univ Antioquia, St 67 53-108 Off 2-118, Medellin, Antioquia, Colombia
[2] Univ Antioquia, Res Grp Pharmaceut Promot & Prevent, Medellin, Colombia
关键词
INFLUENZA;
D O I
10.1016/j.sapharm.2020.03.013
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The infection by the new coronavirus (SARS-CoV-2) has taken the dimension of a pandemic, affecting more than 160 countries in a few weeks. In Colombia, despite the implementation of the rules established by the national government, exists an elevate concern both for mortality and for the limited capacity of the health system to respond effectively to the needs of patients infected. For Colombia, assuming a case fatality rate among people infected with SARS-CoV-2 of 0.6% (average data from the information reported for Latin American countries for March 18) (Table 1), the number of deaths, in one or two weeks, could be 16 and 243, respectively. These estimates differ markedly from those documented in countries such as Spain and Italy, in which COVID-19 case fatality rates exceed 8% (case of Italy) and from the percentage of patients who have required intensive care, which has ranged from 9% to 11% of patients in Mediterranean European countries. These differences could be explained due to: a) the percentage of the population at risk (individuals older than 60 years); b) a higher epidemiological exposure to viral respiratory infections associated with more frequent exposure to them, due to geographic and climatic conditions; c) less spread of the virus by location in the tropical zone; and d) earlier preventive measures to contain the spread of SARS-CoV-2 infection. Therefore, it is possible to establish that the situation in this country will be different from in European Mediterranean and that Colombia could have different endpoints from Spain and Italy.
引用
收藏
页码:2036 / 2039
页数:4
相关论文
共 12 条
[1]   Similar virus spectra and seasonality in paediatric patients with acute respiratory disease, Ghana and Germany [J].
Annan, A. ;
Ebach, F. ;
Corman, V. M. ;
Krumkamp, R. ;
Adu-Sarkodie, Y. ;
Eis-Huebinger, A. M. ;
Kruppa, T. ;
Simon, A. ;
May, J. ;
Evans, J. ;
Panning, M. ;
Drosten, C. ;
Drexler, J. F. .
CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (04) :340-346
[2]  
[Anonymous], Coronavirus Colombia
[3]   IMMUNITY TO INFLUENZA IN MAN [J].
COUCH, RB ;
KASEL, JA .
ANNUAL REVIEW OF MICROBIOLOGY, 1983, 37 :529-549
[4]  
CSSEGISandData, 2020, CSSEGISANDDATA COVID
[5]   Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines [J].
Dong, Wei ;
Bhide, Yoshita ;
Sicca, Federica ;
Meijerhof, Tjarko ;
Guilfoyle, Kate ;
Engelhardt, Othmar G. ;
Boon, Louis ;
de Haan, Cornelis A. M. ;
Carnell, George ;
Temperton, Nigel ;
de Vries-Idema, Jacqueline ;
Kelvin, David ;
Huckriede, Anke .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[6]   Commentary on Ferguson, et al., "Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand" [J].
Eubank, S. ;
Eckstrand, I ;
Lewis, B. ;
Venkatramanan, S. ;
Marathe, M. ;
Barrett, C. L. .
BULLETIN OF MATHEMATICAL BIOLOGY, 2020, 82 (04)
[7]  
Feng ZJ, 2020, CHINA CDC WEEKLY, V2, P113, DOI [10.3760/cma.j.issn.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
[8]   Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion [J].
Huang, Peikai ;
Liu, Tianzhu ;
Huang, Lesheng ;
Liu, Hailong ;
Lei, Ming ;
Xu, Wangdong ;
Hu, Xiaolu ;
Chen, Jun ;
Liu, Bo .
RADIOLOGY, 2020, 295 (01) :22-23
[9]  
O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI [10.1086/344188, 10.1086/502007]
[10]  
Sajadi M, 2020, SSRN ELECT J, V2, P10